529 related articles for article (PubMed ID: 11916233)
1. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.
Vogel VG
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
3. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
[TBL] [Abstract][Full Text] [Related]
4. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
[TBL] [Abstract][Full Text] [Related]
5. Prevention of breast cancer in high-risk women.
Kardinal CG; Veith R
J La State Med Soc; 1999 Apr; 151(4):198-201. PubMed ID: 10234895
[TBL] [Abstract][Full Text] [Related]
6. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
Vogel VG
J Clin Oncol; 2001 Sep; 19(18 Suppl):87S-92S. PubMed ID: 11560980
[TBL] [Abstract][Full Text] [Related]
7. Chemoprevention in postmenopausal women.
Rastogi P
Menopause; 2008; 15(4 Suppl):810-5. PubMed ID: 18596603
[TBL] [Abstract][Full Text] [Related]
8. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
9. The cost effectiveness of tamoxifen in the prevention of breast cancer.
Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of breast cancer.
Dalton RR; Kallab AM
South Med J; 2001 Jan; 94(1):7-15. PubMed ID: 11213947
[TBL] [Abstract][Full Text] [Related]
11. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
12. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Veronesi U; Maisonneuve P; Rotmensz N; Bonanni B; Boyle P; Viale G; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Oliviero P; Lovison F; Gucciardo G; del Turco MR; Muraca MG; Pizzichetta MA; Conforti S; Decensi A;
J Natl Cancer Inst; 2007 May; 99(9):727-37. PubMed ID: 17470740
[TBL] [Abstract][Full Text] [Related]
14. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
15. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
16. The STAR (Study of Tamoxifen and Raloxifene) trial in West Virginia.
Jubelirer SJ; Crowell EB
W V Med J; 2000; 96(6):602-4. PubMed ID: 11194089
[TBL] [Abstract][Full Text] [Related]
17. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
Crowell EB; Jubelirer SJ
W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
[TBL] [Abstract][Full Text] [Related]
19. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
Vogel VG
Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
[TBL] [Abstract][Full Text] [Related]
20. The prevention of breast cancer.
Prichard RS; Hill AD; Dijkstra B; McDermott EW; O'Higgins NJ
Br J Surg; 2003 Jul; 90(7):772-83. PubMed ID: 12854100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
